Market Place
Sourcing Support
All News #Library
Biotech
Shionogi Highlights Fetroja for MBL-Producing Infections
07 Apr 2026 //
PHARMIWEB
Viiv Pharma Unveils Long-Acting HIV Breakthroughs At CROI 2026
17 Feb 2026 //
BUSINESSWIRE
Cumulus Enters Japan to Advance Cognitive Biomarker with Shionogi
10 Feb 2026 //
PR NEWSWIRE
Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits
19 Jan 2026 //
REUTERS
Shionogi Highlights Cefiderocol Role In Diverse Infections
20 Oct 2025 //
PHARMIWEB
Shionogi Offers $600 M for Swiss Biotech`s Antibiotic Program
02 Jul 2025 //
FIERCE BIOTECH
Shionogi`s RSV antiviral reduces viral load in ph. 2 adult trial
30 Jan 2025 //
FIERCE BIOTECH
Shionogi says Phase 3 study showed COVID pill reduces transmission
30 Oct 2024 //
REUTERS
Japan`s Shionogi says COVID treatment did not meet endpoint in late-stage trial
13 May 2024 //
REUTERS
Shionogi Announces Phase 3 Data Showing Early Resolution of COVID-19 Symptoms
09 Feb 2024 //
BUSINESSWIRE
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness
11 Oct 2023 //
BUSINESSWIRE
Brii Bio Announces Agreements with Qpex & Acquiring Global Rights for BRII-693
25 Jun 2023 //
PR NEWSWIRE
Shionogi starts Phase I trial of Covid-19 antiviral in Japan
18 May 2023 //
CLINICAL TRIALS ARENA
Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
04 Apr 2023 //
BUSINESSWIRE
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
27 Feb 2023 //
REUTERS
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
15 Feb 2023 //
BUSINESSWIRE
U.S. NIH starts trial for Shionogi`s COVID-19 pill
15 Feb 2023 //
REUTERS
Shionogi commences Phase I/II/III and Phase III trials of Covid-19 vaccine
17 Jan 2023 //
CLINICAL TRIALS ARENA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.